 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...224225226227228229230231232233234235236 |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Nov 6, 2011
P2, N=25, Recruiting, Sponsor: Drexel University
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 5, 2011
P2, N=68, Recruiting, Sponsor: Samsung Medical Center
- Enrollment open: CALGB-80803: PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Nov 1, 2011
P2, N=204, Recruiting, Sponsor: Cancer and Leukemia Group B
Not yet recruiting --> Recruiting
- | Oncaspar liquid (pegaspargase) / Servier
Clinical: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Oct 24, 2011
P3, N=800, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting N=544 --> 800
- Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy, Metastases: Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX (clinicaltrials.gov) - Oct 13, 2011
P1, N=15, Recruiting, Sponsor: National Taiwan University Hospital
N=544 --> 800 Active, not recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly
Trial termination, IO biomarker, Metastases: Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer (clinicaltrials.gov) - Oct 12, 2011
P1, N=21, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Recruiting Active, not recruiting --> Terminated; Sponsor will discontinue further development of EMD 1201081
- | Trial completion, Metastases: Metastatic Gastric Cancer FFCD 03-07 (clinicaltrials.gov) - Oct 10, 2011
P3, N=416, Completed, Sponsor: University Hospital, Toulouse
Active, not recruiting --> Terminated; Sponsor will discontinue further development of EMD 1201081 Active, not recruiting --> Completed
- New P1 trial: Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer (clinicaltrials.gov) - Oct 3, 2011
P1, N=24, Recruiting, Sponsor: Emory University
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment change, Metastases: Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin (clinicaltrials.gov) - Oct 2, 2011
P2, N=12, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed N=10 --> 12
- |||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: OPUS: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Oct 2, 2011
P2, N=344, Completed, Sponsor: Merck KGaA
N=10 --> 12 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Metastases: Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin (clinicaltrials.gov) - Oct 2, 2011
P2, N=12, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Vectibix (panitumumab) / Amgen, rilotumumab (AMG 102) / Amgen
New P2 trial: MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Sep 27, 2011
P2, N=165, Recruiting, Sponsor: UNICANCER
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Sep 27, 2011
P2, N=256, Recruiting, Sponsor: UNICANCER
- Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial termination: Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-? Blockers (clinicaltrials.gov) - Sep 26, 2011
P2, N=16, Terminated, Sponsor: Sanofi
Active, not recruiting --> Completed Completed --> Terminated; Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: PRODIGE 18: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab (clinicaltrials.gov) - Sep 26, 2011
P2, N=132, Recruiting, Sponsor: UNICANCER
- ||| Stivarga (regorafenib) / Bayer
Enrollment closed, Combination therapy, Metastases: First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib (clinicaltrials.gov) - Sep 18, 2011
P2, N=54, Active, not recruiting, Sponsor: Bayer
Completed --> Terminated; Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns Recruiting --> Active, not recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P1 trial, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Sep 12, 2011
P1, N=30, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- ||| ipatasertib (RG7440) / Roche
Enrollment open, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 12, 2011
P1, N=120, Recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer. (clinicaltrials.gov) - Sep 7, 2011
P2, N=43, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment open, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Sep 1, 2011
P1, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed: Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Aug 31, 2011
P2, N=100, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
New P2 trial: DCE-MRI PET Bevacizumab Study in Rectal Cancer (clinicaltrials.gov) - Aug 29, 2011
P2, N=30, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, Trial completion, HEOR, Metastases: Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer (clinicaltrials.gov) - Aug 28, 2011
P2, N=143, Completed, Sponsor: Krankenhaus Nordwest
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
New P1 trial, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Aug 18, 2011
P1, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- Avastin (bevacizumab) / Roche
Trial termination, Metastases: A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 17, 2011
P1, N=8, Terminated, Sponsor: Accelerated Community Oncology Research Network
Active, not recruiting --> Completed Completed --> Terminated; Dose limiting toxicity at the lowest planned dose level.
- Avastin (bevacizumab) / Roche
Enrollment change, Metastases: A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 17, 2011
P1, N=8, Terminated, Sponsor: Accelerated Community Oncology Research Network
Completed --> Terminated; Dose limiting toxicity at the lowest planned dose level. N=45 --> 8
- |||| Avastin (bevacizumab) / Roche, Erivedge (vismodegib) / Roche
Trial completion, Metastases: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 17, 2011
P2, N=199, Completed, Sponsor: Genentech
N=45 --> 8 Active, not recruiting --> Completed
- ||||| Avastin (bevacizumab) / Roche, onartuzumab (RG3638) / Roche
New P2 trial, Metastases: FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 15, 2011
P2, N=194, Active, not recruiting, Sponsor: Genentech
- ||||| Avastin (bevacizumab) / Roche
New P2 trial, Metastases: PRODIGE-20: 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2011
P2, N=102, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 11, 2011
P1, N=17, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=22 --> 17
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Metastases: Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease (clinicaltrials.gov) - Aug 7, 2011
P3, N=67, Completed, Sponsor: NCIC Clinical Trials Group
N=22 --> 17 N=144 --> 67
- | Rituxan (rituximab) / Roche
New P2 trial: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 7, 2011
P2, N=180, Recruiting, Sponsor: Southwest Oncology Group
- PF-04136309 / Pfizer
New P1 trial, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 7, 2011
P1, N=44, Recruiting, Sponsor: Washington University School of Medicine